PUBLICATION

Global Business Reports

AUTHORS

Neha Premjee, Bryce Stevenson

Indonesia Pharmaceuticals 2015

April 01, 2015

Often underappreciated for its immensity, Indonesia has approximately 250 million people, which makes it the world’s fourth most populous country. Indonesia also plays an outsized role in the region’s economic activity, as its economy is the largest in the Association of South East Asian Nations (ASEAN). Indonesia may be classified as a lower-middle income country, but it offers vast potential in terms of commercial opportunity, particularly in pharmaceuticals. From 2007 to 2013, Indonesia’s pharmaceutical industry grew by 85 percent, including 7% in 2014 alone, and is now valued at $6 billion. Growth is forecasted to rise to 12% in 2015 and to continue through 2018. As Indonesia’s market for pharmaceuticals expands and deepens, domestic and multinational players are positioning themselves to capitalize on emerging opportunities.

 

Featuring exclusive interviews with:

Ministry of Health, Republic of Indonesia – Dr. Maura Linda Sitanggang, Director General of Pharmaceutical Services and Medical Devices
National Board Indonesian Pharmaceutical Association (GP. Farmasi Indonesia) – Dr. Johannes Setijono, Chairman, National Board
National Agency for Drug and Food Control (BPOM) – Roy Sparringa, PhD., Chairman
Menjangan Sakti, Mensa Group – Jonathan Sudharta, Managing Director
Interbat – Derrick Budi Sukamto, Vice President
Combiphar – Michael Wanandi, President Director
Tigaka Distrindo Perkasa (TDP) – Thomas Ricky Harsono, Chief Executive Officer
Ekacitta Dian Persada – Dr. Setiawan Nugroho, President Director
Genero Pharmaceuticals – Alfons Sindupranata, Managing Director
DSM Nutritional Products Indonesia – Haeri Roh-Schmidt, General Manager
Pharos – Dr. Andre Arief Lembong, Chairman
Soho Global Health – Rogelio C. la O’Jr. (Cooey), President Director & Chief Executive Officer

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
Tosk, Inc. is a small molecule, oncology drug discovery and development company.

MACIG

An Industry in Decline: Understanding the Politics behind South Africa’s Downfall

October 02, 2019
Once the mining capital of Africa, South Africa’s decline in regional hegemony is inextricably linked to its fraught sociopolitical fabric.

SUBSCRIBE TO OUR NEWSLETTER